Cell genomics
made easy
Services
We care for your cells
Stem Genomics provides a new test to assess the genomic integrity of stem cells. This innovative test is done using the supernatant collected from your cell cultures that has been shipped at room temperature.
This rapid, sensitive, conclusive and cost-effective test allows the routine monitoring of the genomic integrity of cultured pluripotent stem cells.
The in Culture Supernatant – digital PCR Pluri (iCS-digital TM Pluri) test detects more than 90% of recurrent genomic abnormalities in human pluripotent stem cells (PSC), i.e. human embryonic stem cells (ESC) and induced pluripotent stem cells (iPSC).
The in Culture Supernatant – digital PCR Aneuploidy (iCS-digital TM Aneuploidy) test detects whole chromosome gains & losses in all chromosomes (22 autosome pairs and X and Y chromosomes) and in any human cell type.
The in Culture Supernatant-digital PCR (iCS-digital TM) test allows amplifying very small quantities of DNA that is present in cell culture supernatant and that harbours the cell genetic traits. Taking advantage on its own experience and skills, Stem Genomics can design and run customized assays to meet your specific requirement.
Digital PCR is an ultrasensitive method for absolute quantification of nucleic acids. It is particularly suitable for the detection of low-abundance targets, and for the analysis of allelic variants (single nucleotide polymorphisms, SNPs) and copy number variations (CNVs).
About
Stem Genomics
Stem Genomics develops a technology invented by Prof John De Vos and Dr Said Assou, researchers at the Institute for Regenerative Medicine & Biotherapy (IRMB), University of Montpellier, and co-founders of the company. Located at the heart of the University Hospital Centre of Montpellier, IRMB houses research groups working on basic stem cell research and on innovative applications for regenerative therapy, with the aim of facilitating the transfer from research to clinical applications. Stem Genomics is located at the IRMB Cyborg business incubator and works in close collaboration with IRMB researchers. Stem Genomics has emerged from a prestigious scientific environment.
Visit us at booth #526 to learn more about our services and get your coupon* for a free iCS-digital TM test.
Do not hesitate to request a meeting slot in advance.
26-29 June, 2019 - Los Angeles Convention Center
*This offer is reserved for new customers
Now online
“Recurrent genetic abnormalities in human pluripotent stem cells: definition and routine detection in culture supernatant by targeted droplet digital PCR” by Assou et al.
The unique features of human pluripotent stem cells (hPSCs) open new opportunities for disease modeling, drug discovery and the development of cell-based therapies. However, genetic abnormalities can accumulate during the generation, long-term maintenance or during genome editing of these cells. Therefore, it is crucial to detect these abnormalities as soon as they appear to guaranty the safe and proper use of hPSCs in clinical practice and in research.
To address this issue, Assou et al. performed an exhaustive study by combining data from publications describing the occurrence of hPSC aberrations during in vitro culture. Based on this large meta-analysis, a test called iCS-digital (in culture supernatant-digital PCR) has been designed consisting in a panel of droplet digital PCR probes that target the most recurrent abnormalities identified by these studies.
Thanks to the precision of the digital PCR technology, the iCS-digital test allows the sensitive, precise and absolute quantification of copy number variations (CNVs) and the detection of anomalies that are below the G-banding method resolution, especially the sub-karyotypic 20q11.21 hotspot.
Using the iCS-digital test, Assou et al. could monitor cell integrity through regular screenings, and record the moment where genomic aberrations appeared. Furthermore, the iCS-digital test presents the advantage of using cell culture supernatant instead of intact cells as a DNA source, bypassing the inconvenience of dedicating a certain fraction of cell material for control quality testing.
To conclude, Assou et al. demonstrated the interest of the iCS-digital test for routine hPSC screening, thanks to the simplicity of the collection procedure, the rapidity of the test, and the accuracy of the digital PCR technology. This innovative test can change how hPSC quality control is implemented for their use in basic research, regenerative medicine, and can contribute to secure genome editing workflows.
The iCS-digital TM test is exclusively provided by Stem Genomics as a full service. For more information and quotations, please follow these links:
Download the publication
Discover the test and request a quote